Inclusion of patients with comorbidity and comedication in premarketing trials of cardiovascular drugs

Drug Development Research

Volumn 51, Issue 3, 2000, Pages 159-168

  Wieringa, Nicolien F ^a   Vos, Rein ^b   Van Der Werf, Ger Th ^a   De Graeff, Pieter A ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Cardiovascular agents; Clinical trials; Drug approval; Patient selection; Phase III

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; VASODILATOR AGENT;

ANGINA PECTORIS; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PATIENT SELECTION; TREATMENT INDICATION;

EID: 0034495741     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200011)51:3<159::AID-DDR4>3.0.CO;2-C     Document Type: Article

References (18)

1. Bailey KR. 1994. Generalizing the results of randomized clinical trials. Control Clin Trials 15:15-23.
2. Berry SM. 1998. Understanding and testing for heterogeneity across 2 x 2 tables: application to meta-analysis. Stat Med 17:2353-2369.
3. CPME 1990. Good clinical practice for trials on medicinal products in the European Community. Working Party on efficacy of medicinal products. Brussels: Commission of the European Communities.
4. CPMP/ICH. 1997. General considerations for clinical trials. International Conference on Harmonization. ICH Topic E8. London: European Medicines Evaluation Agency.
5. EMEA. 1993. Studies in support of special populations: geriatrics. ICH Topic E7. (CPMP/ICH/379/95). London: European Medicines Evaluation Agency.
6. FDA. 1978. General considerations for the clinical evaluation of drugs. Rockville, MD: Food and Drug Administration, US Department of Health, Education and Welfare.
7. FDA. 1989. Guidelines for the study of drugs likely to be used in the elderly. Rockville, MD: Food and Drug Administration, US Department of Health, Education and Welfare.
8. Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. 1998. A study of contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. J Clin Epidemiol 51:69-79.
9. Gardner MJ, Altman DG, 1989. Statistics with confidence. Confidence intervals and statistical guidelines. London: British Medical Journal.
10. Holmberg L, Baum M, Adami HO. 1999. On the scientific inference from clinical trials. J Eval Clin Practice 5:157-162.
11. ICD. 1995. The international classification of diseases, 9th revision. Clinical modification (ICD 9 CM). New York: McGraw-Hill.
12. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. 1997. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials 18:328-357.
13. Martindale. 1993. The extra pharmacopoeia, 30th ed. London: Pharmaceutical Press.
14. Po AL, Zhang WY, 1998. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351:1829-1830.
15. Polednak AP. 1989. Cardiovascular diseases. In: Polednak AP. Racial and ethnic differences in disease. Oxford: Oxford University Press, p 125-167.
16. Wei JY. 1992. Age and the cardiovascular system. N Engl J Med 327:1735-1739.
17. WHO. 1995. Anatomical therapeutic chemical (ATC) classification index. Oslo: WHO Collaborating Centre for Drug Statistics Methodolog).
18. Yusuf S, Held P, Teo KK, Toretsky ER. 1990. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med 9:73-83.